Price Chart

Key Stats

Net Expense Ratio Discount or Premium to NAV Total Assets Under Management 30-Day Average Daily Volume
0.59% 0.04% 2.713M 1431.60
Weighted Average Dividend Yield Turnover Ratio (Generic) 1 Year Fund Level Flows Max Drawdown (Since Inception)
1.86% 70.00% -1.637M Upgrade

Basic Info

Investment Strategy
The Fund seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. It invests at least 80% of its net assets in securities that comprise the Index which is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business.
General
Security Type Exchange-Traded Fund
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Amplify ETFs
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Performance Versus Peer Group

 
20%
15%
10%
5%
0
View Category Returns. Upgrade now.
Name
1M
3M
YTD
1Y
3Y
5Y
10Y
15Y
Total Return (Price)
--
--
--
--
--
--
--
--
Total Return (NAV)
--
--
--
--
--
--
--
--
Peer Group Rtn. (NAV)
--
--
--
--
--
--
--
--
% Rank in Peer Group (NAV)
--
--
--
--
--
--
--
--

Annual Total Returns Versus Peers

Loading chart...
Name
2018
2019
2020
2021
2022
2023
2024
YTD
-8.71%
27.67%
15.90%
21.82%
-18.14%
23.79%
18.67%
20.21%
-5.87%
19.40%
5.51%
17.79%
2.62%
6.95%
8.06%
15.01%
-1.47%
25.24%
18.96%
3.91%
-8.62%
9.64%
7.04%
18.27%
--
--
--
--
-28.59%
7.55%
1.79%
1.79%
--
--
--
--
-25.84%
4.50%
1.98%
--
As of December 10, 2025.

Asset Allocation

As of November 30, 2025.
Type % Net
Cash 0.47%
Stock 99.02%
Bond 0.29%
Convertible 0.00%
Preferred 0.00%
Other 0.23%
View Asset Allocation
Start Trial

Basic Info

Investment Strategy
The Fund seeks investment results that generally correspond to the performance of the VettaFi Weight Loss Drug & Treatment Index. It invests at least 80% of its net assets in securities that comprise the Index which is comprised of global companies who are manufacturers in the GLP-1 agonist pharmaceutical business.
General
Security Type Exchange-Traded Fund
Broad Asset Class Sector Equity
Broad Category Equity
Global Peer Group Equity Sector Healthcare
Peer Group Global Health/Biotechnology Funds
Global Macro Equity Industry Sector
US Macro World Sector Equity Funds
YCharts Categorization --
YCharts Benchmark --
Prospectus Objective Global Health/Biotechnology Funds
Fund Owner Firm Name Amplify ETFs
Broad Asset Class Benchmark Index
^MSWNTR 100.0%

View Basic Info
Start Trial

Top Portfolio Holders